BIOYF Stock BioSyent (BIOYF, $8.81) was a top weekly gainer, with a +7.43% jump
at Tickeron.com
Loading...
BioSyent (BIOYF, $8.81) was one of the top gainers this week, climbing to $8.81 per share. A.I.dvisor analyzed 227 stocks in the Pharmaceuticals: Generic Industry over the last week and discovered that of them (7) trended up while of them (2) trended down.
BIOYF in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2025
BIOYF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where BIOYF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIOYF's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where BIOYF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BIOYF just turned positive on November 07, 2025. Looking at past instances where BIOYF's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOYF advanced for three days, in of 115 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOYF as a result. In of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOYF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BIOYF entered a downward trend on November 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.239) is normal, around the industry mean (18.491). P/E Ratio (15.303) is within average values for comparable stocks, (71.901). BIOYF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.834). Dividend Yield (0.018) settles around the average of (0.030) among similar stocks. P/S Ratio (3.187) is also within normal values, averaging (55.234).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BIOYF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Advertisement
General Information
Industry PharmaceuticalsGeneric